Fig. 1

Description of patient cohorts and study schema. (a) Study schema showing the collection of microbiome samples from three separate body sites. Samples undergo 16S rRNA amplicon sequencing followed by taxonomic profiling. The resulting data is correlated to clinical outcomes such as response to ICI therapy or development of AEs. (b) An abbreviated demographics chart summarizing notable disease and patient characteristics of LC contributors. For granular individual characteristics, please refer to Supplemental Table 1. (c) Breakdown of patients belonging to each study cohort. ICI = immune checkpoint inhibitor. Checkpoint inhibitor status (number of patients enrolled – number of fecal samples that were unable to be analyzed or not submitted – number of nasal/buccal samples that were unable to be analyzed or not submitted